Skip to main content
Clinical Trials/NCT02699944
NCT02699944
Completed
N/A

Optimization of Cardiac Resynchronization Therapy Using an ECG Vest

Alan J. Bank, MD1 site in 1 country56 target enrollmentNovember 2015
ConditionsHeart Failure

Overview

Phase
N/A
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Alan J. Bank, MD
Enrollment
56
Locations
1
Primary Endpoint
Change in left ventricular end-systolic volume
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Despite advancements in implant technology and various techniques of optimization, there is still around 30% non-responder rate to cardiac resynchronization therapy (CRT). This study will assess the potential benefit of a body surface mapping technology to optimize CRT devices in the chronic sub-optimal responder setting.

Detailed Description

Cardiac resynchronization therapy (CRT) is one of the most important advances in the treatment of patients with heart failure (HF). This therapy, also known as biventricular pacing, utilizes pacemaker leads to synchronize the contraction of the walls within the left ventricle (LV) and the contraction of the left and right ventricles. Many randomized trials have conclusively demonstrated that CRT improves symptoms, LV structure and function, hospitalization rates, and survival in appropriately selected HF patients. Nonetheless, approximately 30% of CRT patients will be "non-responders" because they will not demonstrate the expected clinical and/or echocardiographic improvement following therapy. A critical component of assessing CRT efficacy during the optimization clinic will be the use of a novel method of body surface electrocardiographic mapping under development by Medtronic, called the ECG Vest. In this proposal, we describe a research study to assess the potential benefit of using the ECG Vest as part of a CRT optimization strategy on clinical and echocardiographic outcomes (heart size and function) of patients receiving standard clinical care in the UHVC CRT Optimization Clinic.

Registry
clinicaltrials.gov
Start Date
November 2015
End Date
August 17, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Alan J. Bank, MD
Responsible Party
Sponsor Investigator
Principal Investigator

Alan J. Bank, MD

Medical Director of Research

Allina Health System

Eligibility Criteria

Inclusion Criteria

  • Patients (or their legal guardian) must be willing to provide Informed Consent and a data privacy (HIPPA) authorization
  • Patient is or will be followed clinically in the UHVC CRT Optimization Clinic
  • Patient has been implanted with a CRT device for at least 6 months
  • Patient received an echocardiogram prior to CRT implant
  • Patients must be ≥ 18 years of age

Exclusion Criteria

  • Patient's EF is currently ≥ 50%
  • Patients who are pregnant
  • Patient has unhealed / open wounds on the torso and/or has a history of severe allergic reactions from ECG gel / electrode glue

Outcomes

Primary Outcomes

Change in left ventricular end-systolic volume

Time Frame: 6 months after optimization

Secondary Outcomes

  • Determine the degree to which echocardiographic measures of LV function correlate with ECG Vest measures(6 months after optimization)

Study Sites (1)

Loading locations...

Similar Trials